{"id":12819,"date":"2025-01-28T06:30:00","date_gmt":"2025-01-28T06:30:00","guid":{"rendered":"https:\/\/www.xvivogroup.com\/us\/mfn_news\/year-end-report-2024\/"},"modified":"2025-01-28T06:30:00","modified_gmt":"2025-01-28T06:30:00","slug":"year-end-report-2024","status":"publish","type":"mfn_news","link":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/year-end-report-2024\/","title":{"rendered":"Year-end report 2024"},"content":{"rendered":"
\n

Fourth quarter 2024 (October 1 – December 31)<\/strong>
\u2022 Net sales amounted to SEK 227.6 million (155.7), corresponding to growth of 46 percent in SEK and 45 percent in local currencies.
\u2022 Organic growth accounted for 44 percent and acquired growth for 1 percent. All business areas delivered underlying organic growth adjusted for currency effects: Thoracic disposables 50 percent, Abdominal disposables 35 percent and Services 16 percent.
\u2022 Gross margin for disposables was 82 percent (81). The total gross margin increased to 77 percent (75).
\u2022 Operating income (EBIT) increased to SEK 15.5 million (-16.1) and includes a write-down of intangible assets of SEK -20.1 million (-16.4) related to discontinued development projects. Adjusted EBIT amounted to SEK 36.6 million (0.8).
\u2022 Operating income before depreciation and amortization (EBITDA) increased to SEK 51.9 million (20.7), corresponding to an EBITDA margin of 23 percent (13). Adjusted operating income before depreciation and amortization (EBITDA) amounted to SEK 52.9 million (21.2), corresponding to an adjusted EBITDA margin of 23 percent (14).
\u2022 Net profit amounted to SEK 36.4 million (68.5) and was impacted by financial expenses of SEK -0.4 million (73.7) attributable to fair value valuation of financial liabilities.
\u2022 Earnings per share amounted to SEK 1.16 (2.17).
\u2022 Cash flow from operating activities was SEK 62.1 million (18.1). Total cash flow amounted to SEK -51.7 million (-38.2) primarily impacted by investments in R&D projects, production facilities and the acquisition of FlowHawk.<\/p>\n

Significant events in the quarter<\/strong>
\u2022 Enrollment of patients completed five months early in XVIVO\u2019s clinical trial in the US evaluating heart preservation technology
\u2022 Lena Hagman is appointed deputy CEO<\/p>\n

The period 2024 (January 1 – December 31)<\/strong>
\u2022 Net sales amounted to SEK 822.4 million (597.5), corresponding to growth of 38 percent in SEK and 39 percent in local currencies.
\u2022 Organic growth accounted for 39 percent, currency effect -1 percent. All business areas delivered underlying organic growth adjusted for currency effects: Thoracic disposables 46 percent, Abdominal disposables 32 percent and Services 7 percent.
\u2022 Gross margin for disposables was 81 percent (81). The total gross margin increased to 75 percent (74).
\u2022 Operating income (EBIT) increased to SEK 88.4 million (4.2) and includes a write-down of intangible assets of SEK -20.3 million (-16.4) related to discontinued development projects. Adjusted EBIT amounted to SEK 115.6 million (42.7).
\u2022 Operating income before depreciation and amortization (EBITDA) increased to SEK 176.1 million (80.5), corresponding to an EBITDA margin of 21 percent (13). Adjusted operating income before depreciation and amortization (EBITDA) amounted to SEK 183.1 million (102.6), corresponding to an adjusted EBITDA margin of 22 percent (17).
\u2022 Net profit increased to SEK 172.2 million (91.8) and was impacted by financial income of SEK 59.0 million (72.0) attributable to fair value valuation of financial liabilities.
\u2022 Earnings per share amounted to SEK 5.47 (3.07).
\u2022 Cash flow from operating activities increased to SEK 111.3 million (46.3). Total cash flow amounted to SEK -143.4 million (303.2) primarily impacted by investments in R&D projects, production facilities, and the acquisition of FlowHawk.<\/p>\n

Significant events in the reporting period<\/strong>
\u2022 First-ever transplantation of a donor heart transported across the Atlantic – made possible by XVIVO\u2019s heart technology
\u2022 Study in extended hypothermic (cold) perfusion of liver using Liver Assist shows that preservation can last up to 20 hours.
\u2022 New clinical study, \u2018HOPE at Heart\u2019, started by XVIVO in Europe on DCD hearts in 20 patients
\u2022 Unique initiative, \u2019The Bridge \u2013 Lungs for Life\u2019, started to increase lung transplants in Sweden and Denmark
\u2022 Results of XVIVO\u2019s European heart preservation study published in The Lancet
\u2022 XVIVO signs agreement to acquire FlowHawk \u2013 a unique communication platform for the transplant process. The transaction was completed on October 11<\/p>\n

Events after the end of the period<\/strong>
\u2022 IDE application filed with the FDA in the US for approval to start a clinical trial with Liver Assist
\u2022 XVIVO has entered into a revolving credit facility of EUR 20 million with a three year term. The credit facility provides XVIVO with further flexibility for strategic management of growth opportunities, financing working capital and general business purposes<\/p>\n

CEO comment<\/strong>
\u201cDuring 2024 we estimate that more than 12,000 patients were given a lifesaving transplant using XVIVO\u00b4s products or services. It has been a strong year for XVIVO, marked by topline growth and encouraging progress in clinical and regulatory activities. As we look ahead, we remain committed to our vision that \u2018no one should die waiting for a new organ\u2019<\/em>. We will continue to push the boundaries of organ transplantation and improve outcomes for patients worldwide. The achievements of the past year, combined with the exciting opportunities on the horizon, position XVIVO for rapid but sustained growth. None of this would be possible without the trust and enthusiasm of our customers and the dedication of our employees. Together, we are shaping the future of organ transplantation, and I am confident that 2025 will be another impactful year for XVIVO.\u201d – Christoffer Rosenblad, CEO<\/p>\n<\/div>\n

\n

For further information, please contact:<\/strong><\/p>\n

\n

Christoffer Rosenblad, CEO, +46 73 519 21 59, e-mail: christoffer.rosenblad@xvivogroup.com
Kristoffer\u00a0Nordstr\u00f6m, CFO, +46 73 519 21 64, e-mail:\u00a0kristoffer.nordstrom@xvivogroup.com<\/p>\n<\/div>\n

\n

Conference Call<\/strong><\/p>\n

\n

Christoffer Rosenblad, CEO and Kristoffer Nordstr\u00f6m, CFO, will present the report in a conference call today at 2.00 PM CET \/ 8.00 AM EST. For registration to the conference call, see information in previous press release: https:\/\/www.xvivogroup.com\/us\/pressreleases\/conference-call-on-year-end-report-2024\/<\/p>\n<\/div>\n

\n

About Us<\/strong><\/p>\n

\n

Founded in 1998, XVIVO is the only medical technology company dedicated to extending the life of all major organs – so transplant teams around the world can save more lives. Our solutions allow leading clinicians and researchers to push the boundaries of transplantation medicine. XVIVO is headquartered in Gothenburg, Sweden, and has offices and research sites on two continents. The company is listed on Nasdaq Stockholm under the ticker symbol XVIVO. More information can be found on the website www.xvivogroup.com\/us.<\/p>\n<\/div>\n

\n

This information is information that XVIVO Perfusion AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2025-01-28 07:30 CET.<\/em><\/p>\n<\/div>\n

\n

Attachments<\/strong><\/p>\n

\n

XVIVO Year End Report 2024<\/a><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

Fourth quarter 2024 (October 1 – December 31)\u2022 Net sales amounted to SEK 227.6 million (155.7), corresponding to growth of…<\/p>\n","protected":false},"template":"","class_list":["post-12819","mfn_news","type-mfn_news","status-publish","hentry","mfn-news-tag-mfn","mfn-news-tag-mfn-type-ir","mfn-news-tag-mfn-lang-en","mfn-news-tag-mfn-regulatory","mfn-news-tag-mfn-regulatory-mar","mfn-news-tag-mfn-report","mfn-news-tag-mfn-report-interim","mfn-news-tag-mfn-report-interim-q4"],"acf":[],"yoast_head":"\nYear-end report 2024 - XVIVO<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.xvivogroup.com\/us\/pressreleases\/year-end-report-2024\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Year-end report 2024 - XVIVO\" \/>\n<meta property=\"og:description\" content=\"Fourth quarter 2024 (October 1 – December 31)\u2022 Net sales amounted to SEK 227.6 million (155.7), corresponding to growth of...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.xvivogroup.com\/us\/pressreleases\/year-end-report-2024\/\" \/>\n<meta property=\"og:site_name\" content=\"United States\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/pressreleases\\\/year-end-report-2024\\\/\",\"url\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/pressreleases\\\/year-end-report-2024\\\/\",\"name\":\"Year-end report 2024 - XVIVO\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/#website\"},\"datePublished\":\"2025-01-28T06:30:00+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/pressreleases\\\/year-end-report-2024\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/pressreleases\\\/year-end-report-2024\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/pressreleases\\\/year-end-report-2024\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Year-end report 2024\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/#website\",\"url\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/\",\"name\":\"United States\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Year-end report 2024 - XVIVO","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/year-end-report-2024\/","og_locale":"en_US","og_type":"article","og_title":"Year-end report 2024 - XVIVO","og_description":"Fourth quarter 2024 (October 1 – December 31)\u2022 Net sales amounted to SEK 227.6 million (155.7), corresponding to growth of...","og_url":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/year-end-report-2024\/","og_site_name":"United States","twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/year-end-report-2024\/","url":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/year-end-report-2024\/","name":"Year-end report 2024 - XVIVO","isPartOf":{"@id":"https:\/\/www.xvivogroup.com\/us\/#website"},"datePublished":"2025-01-28T06:30:00+00:00","breadcrumb":{"@id":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/year-end-report-2024\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.xvivogroup.com\/us\/pressreleases\/year-end-report-2024\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/year-end-report-2024\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.xvivogroup.com\/us\/"},{"@type":"ListItem","position":2,"name":"Year-end report 2024"}]},{"@type":"WebSite","@id":"https:\/\/www.xvivogroup.com\/us\/#website","url":"https:\/\/www.xvivogroup.com\/us\/","name":"United States","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.xvivogroup.com\/us\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"_links":{"self":[{"href":"https:\/\/www.xvivogroup.com\/us\/wp-json\/wp\/v2\/mfn_news\/12819","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.xvivogroup.com\/us\/wp-json\/wp\/v2\/mfn_news"}],"about":[{"href":"https:\/\/www.xvivogroup.com\/us\/wp-json\/wp\/v2\/types\/mfn_news"}],"wp:attachment":[{"href":"https:\/\/www.xvivogroup.com\/us\/wp-json\/wp\/v2\/media?parent=12819"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}